Amajor challenge in cancer research is the complexity of the tumor microenvironment, which includes the host immunological setting. Inspired by the emerging technology of organ-on-chip, we achieved 3D co-cultures in microfluidic devices (integrating four cell populations: cancer, immune, endothelial, and fibroblasts) to reconstitute ex vivo a human tumor ecosystem (HER2 + breast cancer). We visualized and quantified the complex dynamics of this tumor-onchip, in the absence or in the presence of the drug trastuzumab (Herceptin), a targeted antibody therapy directed against the HER2 receptor. We uncovered the capacity of the drug trastuzumab to specifically promote long cancer-immune interactions (> 50 min), recapitulating an anti-tumoral ADCC (antibody-dependent cell-mediated cytotoxicity) immune response. Cancer-associated fibroblasts (CAFs) antagonized the effects of trastuzumab. These observations constitute a proof of concept that tumors-on-chip are powerful platforms to study ex vivo immunocompetent tumormicroenvironments, to characterize ecosystem-level drug responses, and to dissect the roles of stromal components.

Nguyen, M., De Ninno, A., Mencattini, A., Mermet-Meillon, F., Fornabaio, G., Evans, S.s., et al. (2018). Dissecting Effects of Anti-cancer Drugs and Cancer-Associated Fibroblasts by On-Chip Reconstitution of Immunocompetent Tumor Microenvironments. CELL REPORTS, 25(13), 3884-3893 [10.1016/j.celrep.2018.12.015].

Dissecting Effects of Anti-cancer Drugs and Cancer-Associated Fibroblasts by On-Chip Reconstitution of Immunocompetent Tumor Microenvironments

Mencattini A.;Martinelli E.;
2018-01-01

Abstract

Amajor challenge in cancer research is the complexity of the tumor microenvironment, which includes the host immunological setting. Inspired by the emerging technology of organ-on-chip, we achieved 3D co-cultures in microfluidic devices (integrating four cell populations: cancer, immune, endothelial, and fibroblasts) to reconstitute ex vivo a human tumor ecosystem (HER2 + breast cancer). We visualized and quantified the complex dynamics of this tumor-onchip, in the absence or in the presence of the drug trastuzumab (Herceptin), a targeted antibody therapy directed against the HER2 receptor. We uncovered the capacity of the drug trastuzumab to specifically promote long cancer-immune interactions (> 50 min), recapitulating an anti-tumoral ADCC (antibody-dependent cell-mediated cytotoxicity) immune response. Cancer-associated fibroblasts (CAFs) antagonized the effects of trastuzumab. These observations constitute a proof of concept that tumors-on-chip are powerful platforms to study ex vivo immunocompetent tumormicroenvironments, to characterize ecosystem-level drug responses, and to dissect the roles of stromal components.
2018
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore ING-INF/01 - ELETTRONICA
English
HER2(+) breast cancer; cancer-associated fibroblasts; immunotherapy; live cell imaging; microfluidics; organ-on-chip; pre-clinical models; trastuzumab; tumor microenvironment; tumor-on-chip; Animals; Antineoplastic Agents; Cancer-Associated Fibroblasts; Cattle; Cell Communication; Cell Line, Tumor; Human Umbilical Vein Endothelial Cells; Humans; Immunocompetence; Neoplasm Invasiveness; Receptor, ErbB-2; Stromal Cells; Trastuzumab; Tumor Microenvironment
Nguyen, M., De Ninno, A., Mencattini, A., Mermet-Meillon, F., Fornabaio, G., Evans, S.s., et al. (2018). Dissecting Effects of Anti-cancer Drugs and Cancer-Associated Fibroblasts by On-Chip Reconstitution of Immunocompetent Tumor Microenvironments. CELL REPORTS, 25(13), 3884-3893 [10.1016/j.celrep.2018.12.015].
Nguyen, M; De Ninno, A; Mencattini, A; Mermet-Meillon, F; Fornabaio, G; Evans, Ss; Cossutta, M; Khira, Y; Han, W; Sirven, P; Pelon, F; Di Giuseppe, D;...espandi
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S2211124718319260-main.pdf

solo utenti autorizzati

Licenza: Copyright dell'editore
Dimensione 3.85 MB
Formato Adobe PDF
3.85 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/232358
Citazioni
  • ???jsp.display-item.citation.pmc??? 62
  • Scopus 123
  • ???jsp.display-item.citation.isi??? 116
social impact